P. Mugyenyi

M. Dietrich, S. Rüsch-Gerdes, T. Lutalo, 1995, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30–49 vs ≥50 mL/min

C. Gilks, A. Walker, D. Gibb, 2019, PloS one.

Superior virological suppression with nevirapine/zidovudine/lamivudine versus abacavir/zidovudine/lamivudine without evidence of clinical benefit to 48 weeks: a randomised comparison in patients with low CD4 counts in Africa.

P. Kaleebu, C. Gilks, D. Gibb, 2007 .

Immediate Antiretroviral Therapy Reduces Risk of Infection-Related Cancer During Early HIV Infection.

M. Johnson, T. Wilkin, S. Pujari, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

T cell activation, apoptosis and cytokine dysregulation in the (co)pathogenesis of HIV and pulmonary tuberculosis (TB)

G. Vanham, Z. Toossi, J. Ellner, 2000, Clinical and experimental immunology.

Multiple Validated Measures of Adherence Indicate High Levels of Adherence to Generic HIV Antiretroviral Therapy in a Resource-Limited Setting

D. Bangsberg, C. Kityo, E. Charlebois, 2004, Journal of acquired immune deficiency syndromes.

Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda

O. Laeyendecker, D. Bangsberg, T. Quinn, 2007, AIDS.

Highly active antiretroviral therapy

P. Mugyenyi, 2004, BMJ : British Medical Journal.

Low Incidence of Abacavir Hypersensitivity Reaction Among African Children Initiating Antiretroviral Therapy

P. Mugyenyi, A. Kekitiinwa, K. Nathoo, 2011, The Pediatric infectious disease journal.

Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48‐week randomized comparison with abacavir/zidovudine/lamivudine in HIV‐infected Ugandan adults with low CD4 cell counts

C. Gilks, J. Darbyshire, D. Gibb, 2010, HIV medicine.

Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial

P. Easterbrook, H. Namata, A. Siika, 2018, The Lancet. Infectious diseases.

Global threat from drug resistant HIV in sub-Saharan Africa

T. R. D. Wit, C. Kityo, R. Hamers, 2012, BMJ : British Medical Journal.

Antiretroviral treatment in resource-poor settings: clinical research priorities

D. Katzenstein, H. Masur, J. Mukherjee, 2002, The Lancet.

Two-way mobile phone intervention compared with standard-of-care adherence support after second-line antiretroviral therapy failure: a multinational, randomised controlled trial.

M. Hughes, R. Gross, J. Mellors, 2019, The Lancet. Digital health.

Mechanisms of Apoptosis of T-Cells in Human Tuberculosis

John L. Johnson, Z. Toossi, J. Ellner, 2005, Journal of Clinical Immunology.

Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial

A. Walker, P. Musoke, D. Gibb, 2013, The Lancet.

Diminishing Availability of Publicly Funded Slots for Antiretroviral Initiation among HIV-Infected ART-Eligible Patients in Uganda

Jeffrey N. Martin, D. Bangsberg, E. Geng, 2010, PloS one.

Induction of opsonophagocytic killing activity with pneumococcal conjugate vaccine in human immunodeficiency virus-infected Ugandan adults.

Meng Chen, F. Ssali, C. Kityo, 2008, Vaccine.

Increased Replication of HIV‐1 at Sites of Mycobacterium tuberculosis Infection: Potential Mechanisms of Viral Activation

John L. Johnson, Z. Toossi, J. Ellner, 2001, Journal of acquired immune deficiency syndromes.

This information is current as Activation Infection Is Associated with Immune Depletion of Regulatory T Cells in HIV

N. Jones, C. Kityo, P. Mugyenyi, 2005 .

Oropharyngeal colonization by Streptococcus pneumoniae among HIV-infected adults in Uganda: assessing prevalence and antimicrobial susceptibility.

D. Blossom, C. Kityo, M. Joloba, 2006, International Journal of Infectious Diseases.

Dynamic logistic regression model and population attributable fraction to investigate the association between adherence, missed visits and mortality: a study of HIV-infected adults surviving the first year of ART

Pauliina Ilmonen, H. Oja, A. Walker, 2013, BMC Infectious Diseases.

Scale-up of HIV Treatment Through PEPFAR: A Historic Public Health Achievement

W. El-Sadr, I. Sanne, A. Whiteside, 2012, Journal of acquired immune deficiency syndromes.

Evolution of drug resistance after virological failure of a first-line highly active antiretroviral therapy regimen in Uganda

M. Dybul, R. Dewar, T. Quinn, 2009, Antiviral therapy.

Towards 90-90-90 Target: Factors Influencing Availability, Access, and Utilization of HIV Services—A Qualitative Study in 19 Ugandan Districts

C. Kityo, F. Bajunirwe, P. Mugyenyi, 2018, BioMed research international.

Oral abstracts of the 21st International AIDS Conference 18–22 July 2016, Durban, South Africa

Michael I. Jordan, Donald A. Jackson, J. G. Ndirangu, 2016, Journal of the International AIDS Society.

Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial

P. Easterbrook, T. Peto, N. French, 2017, The lancet. HIV.

T cell activation in HIV-seropositive Ugandans: differential associations with viral load, CD4+ T cell depletion, and coinfection.

N. Jones, C. Kityo, P. Mugyenyi, 2005, The Journal of infectious diseases.

Expression of chemokine receptors on CD4+ T cells in peripheral blood from HIV-infected individuals in Uganda.

K. Matsushima, R. Mugerwa, P. Mugyenyi, 2000, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

Enhanced infection prophylaxis reduces mortality in severely immunosuppressed HIV-infected adults and older children initiating antiretroviral therapy in Kenya, Malawi, Uganda and Zimbabwe: the REALITY trial

K. Maitland, A. Siika, C. Kityo, 2016 .

Efficacy and safety of a combination of azithromycin and chloroquine for the treatment of uncomplicated Plasmodium falciparum malaria in two multi-country randomised clinical trials in African adults

A. Sié, K. Kain, A. Oduro, 2014, Malaria Journal.

Sustainable and cost-effective monitoring of patients on ART.

D. Gibb, P. Mugyenyi, 2014, The Lancet. Global health.

Clinical Differences between Younger and Older Adults with HIV/AIDS Starting Antiretroviral Therapy in Uganda and Zimbabwe: A Secondary Analysis of the DART Trial

Sujal M. Parikh, A. Semeere, C. Kityo, 2013, PloS one.

Prevalence, Incidence and Predictors of Severe Anaemia with Zidovudine-Containing Regimens in African Adults with HIV Infection within the Dart Trial

A. Walker, C. Gilks, J. Darbyshire, 2005, Antiviral therapy.

Hematological reference ranges among healthy Ugandans

R. Grant, T. Lutalo, P. Mugyenyi, 1995, Clinical and diagnostic laboratory immunology.

HIV-associated anemia after 96 weeks on therapy: determinants across age ranges in Uganda and Zimbabwe.

A. Walker, F. Ssali, C. Kityo, 2014, AIDS Research and Human Retroviruses.

High Level of Viral Suppression and Low Switch Rate to Second-Line Antiretroviral Therapy among HIV-Infected Adult Patients Followed over Five Years: Retrospective Analysis of the DART Trial

P. Kaleebu, D. Pillay, A. Walker, 2014, PloS one.

Immunogenicity of a recombinant human immunodeficiency virus (HIV)-canarypox vaccine in HIV-seronegative Ugandan volunteers: results of the HIV Network for Prevention Trials 007 Vaccine Study.

B. Walker, P. Kaleebu, N. Jones, 2003, The Journal of infectious diseases.

Short communication: high rates of thymidine analogue mutations and dual-class resistance among HIV-infected Ugandan children failing first-line antiretroviral therapy.

T. F. Rinke de Wit, C. Kityo, R. Hamers, 2013, AIDS research and human retroviruses.

Mortality in the Year Following Antiretroviral Therapy Initiation in HIV-Infected Adults and Children in Uganda and Zimbabwe

C. Gilks, E. Katabira, A. Walker, 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Using Exclusion-Based Sample Preparation (ESP) to Reduce Viral Load Assay Cost

D. Beebe, S. Berry, H. M. Pezzi, 2015, PloS one.

Human Immunodeficiency Virus-Specific Responses in Adult Ugandans: Patterns of Cross-Clade Recognition

N. Jones, C. Kityo, P. Mugyenyi, 2005, Journal of Virology.

Clinical course of human immunodeficiency virus type 1 associated pulmonary tuberculosis during short-course antituberculosis therapy.

M. Dietrich, S. Ruesch-Gerdes, C. Kityo, 1997, East African medical journal.

PHARYNGEAL COLONIZATION BY KINGELLA KINGAE IN CHILDREN WITH INVASIVE DISEASE

E. Mills, P. Olupot-Olupot, C. Kityo, 2009, The Pediatric infectious disease journal.

When prevention of mother-to-child HIV transmission fails: preventing pretreatment drug resistance in African children.

T. F. Rinke de Wit, R. Hamers, P. Mugyenyi, 2017, AIDS.

The effect of AIDS defining conditions on immunological recovery among patients initiating antiretroviral therapy at Joint Clinical Research Centre, Uganda

E. Katabira, F. Ssali, P. Mugyenyi, 2009, AIDS research and therapy.

Scaling up antiretroviral therapy : experience of the Joint Clinical Research Centre (JCRC) access programme

F. Ssali, C. Kityo, P. Mugyenyi, 2006 .

Factors Associated with Condom Use Among HIV Clients in Stable Relationships with Partners at Varying Risk for HIV in Uganda

G. Ryan, G. Wagner, I. Holloway, 2010, AIDS and Behavior.

Expanding HIV care in Africa: making men matter

N. Ford, E. Mills, P. Mugyenyi, 2009, The Lancet.

HIV vaccines: the Uganda experience.

P. Mugyenyi, 2002, Vaccine.

Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa

K. Maitland, A. Siika, D. Gibb, 2017, The New England journal of medicine.

Causes and Timing of Mortality and Morbidity Among Late Presenters Starting Antiretroviral Therapy in the REALITY Trial

J. Seeley, A. Walker, N. Klein, 2018 .

Barriers to Initiation of Pediatric HIV Treatment in Uganda: A Mixed-Method Study

T. F. Rinke de Wit, T. S. Boender, C. Kityo, 2012, AIDS research and treatment.

Reduced bacterial skin infections in HIV-infected African children randomized to long-term cotrimoxazole prophylaxis

A. Walker, D. Gibb, P. Mugyenyi, 2016, AIDS.

A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration.

M. Vjecha, D. Hom, J. Ellner, 1997, The New England journal of medicine.

A Case of Cryptococcal Lymphadenitis in an HIV-Infected Child.

F. Ssali, C. Kityo, P. Mugyenyi, 2011, AIDS research and human retroviruses.

Affordable HIV drug-resistance testing for monitoring of antiretroviral therapy in sub-Saharan Africa.

T. Peter, W. Stevens, R. Hamers, 2016, The Lancet. Infectious diseases.

No Need for Apologies

W. El-Sadr, P. Mugyenyi, G. Gonsalves, 2011, Journal of acquired immune deficiency syndromes.

Higher sequence diversity in the vaginal tract than in blood at early HIV-1 infection

C. Morrison, Pai-Lien Chen, C. Kwok, 2018, PLoS pathogens.

Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals.

L. Aarons, R. Autar, S. Khoo, 2008, The Journal of antimicrobial chemotherapy.

Adherence to HIV antiretroviral therapy in HIV+ Ugandan patients purchasing therapy

D. Bangsberg, E. Katabira, P. Mugyenyi, 2005, International journal of STD & AIDS.

High prevalence of antiretroviral resistance in treated Ugandans infected with non-subtype B human immunodeficiency virus type 1.

C. Petropoulos, E. Paxinos, E. Arts, 2004, AIDS research and human retroviruses.

Timing of antiretroviral therapy for HIV-1 infection and tuberculosis.

Lerato Mohapi, Ian Sanne, Peter Mugyenyi, 2011, The New England journal of medicine.

Pharmacokinetics of Zidovudine Dosed Twice Daily According to World Health Organization Weight Bands in Ugandan HIV-infected Children

A. Walker, P. Musoke, D. Gibb, 2014, The Pediatric infectious disease journal.

A radiolabeled oligonucleotide ligation assay demonstrates the high frequency of nevirapine resistance mutations in HIV type 1 quasispecies of NVP-treated and untreated mother-infant pairs from Uganda.

Matthew S. Lalonde, E. Arts, F. Bajunirwe, 2008, AIDS research and human retroviruses.

Antiretroviral therapy and sexual behavior: a comparative study between antiretroviral- naive and -experienced patients at an urban HIV/AIDS care and research center in Kampala, Uganda.

G. Colfax, D. Serwadda, D. Bangsberg, 2005, AIDS patient care and STDs.

Antiretroviral drug resistance profiles and response to second-line therapy among HIV type 1-infected Ugandan children.

Peter Mugyenyi, Francis Ssali, Robert Colebunders, 2013, AIDS research and human retroviruses.

Response to antiretroviral therapy of HIV type 1-infected children in urban and rural settings of Uganda.

F. Ssali, C. Kityo, R. Colebunders, 2012, AIDS research and human retroviruses.

The clinical pattern, prevalence, and factors associated with immune reconstitution inflammatory syndrome in Ugandan children

D. Boulware, P. Mugyenyi, E. Mworozi, 2010, AIDS.

Pretreatment HIV drug resistance results in virological failure and accumulation of additional resistance mutations in Ugandan children

T. F. Rinke de Wit, T. S. Boender, C. Kityo, 2017, The Journal of antimicrobial chemotherapy.

Characterization of a Subtype D Human Immunodeficiency Virus Type 1 Isolate That Was Obtained from an Untreated Individual and That Is Highly Resistant to Nonnucleoside Reverse Transcriptase Inhibitors

C. Petropoulos, E. Paxinos, Heather A Baird, 2004, Journal of Virology.

Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial

A. Walker, P. Musoke, W. Snowden, 2010, Antiviral therapy.

Pharmacokinetics of Once versus Twice Daily Lamivudine and Abacavir in HIV-1 Infected Ugandan Children in the ARROW trial.

P. Musoke, W. Snowden, P. Mugyenyi, 2009 .

Efficacy and safety of a combination of azithromycin and chloroquine for the treatment of uncomplicated Plasmodium falciparum malaria in two multi-country randomised clinical trials in African adults

A. Sié, K. Kain, A. Oduro, 2014, Malaria Journal.

Translocated microbiome composition determines immunological outcome in treated HIV infection

M. Lederman, D. Douek, J. Brenchley, 2021, Cell.

Supporting Information S1

Charles F. Gilks, Heiner Grosskurth, Peter Mugyenyi, 2010 .

Instability of tuberculin and Candida skin test reactivity in HIV-infected Ugandans. The Uganda-Case Western Reserve University Research Collaboration.

J. Ellner, R. Huebner, R. Wallis, 1998, American journal of respiratory and critical care medicine.

Identification of gaps for implementation science in the HIV prevention, care and treatment cascade; a qualitative study in 19 districts in Uganda

C. Kityo, F. Bajunirwe, P. Mugyenyi, 2016, BMC Research Notes.

Impact of tuberculosis (TB) on HIV‐1 activity in dually infected patients

D. Hom, Z. Toossi, J. Ellner, 2001, Clinical and experimental immunology.

Coinfection with Schistosoma mansoni Is Associated with Decreased HIV-Specific Cytolysis and Increased IL-10 Production1

N. Jones, F. Ssali, P. Mugyenyi, 2005, The Journal of Immunology.

Cytolysis and Increased IL-10 Production Associated with Decreased HIV-Specific Is Schistosoma mansoni Coinfection with Huyen

N. Jones, F. Ssali, P. Mugyenyi, 2005 .

CD4 T cell activation as a predictor for treatment failure in Ugandans with Plasmodium falciparum malaria.

P. Rosenthal, G. Dorsey, Heidi Hopkins, 2006, The American journal of tropical medicine and hygiene.

Depletion of Regulatory T Cells in HIV Infection Is Associated with Immune Activation1

N. Jones, C. Kityo, P. Mugyenyi, 2005, The Journal of Immunology.

Infecting HIV-1 Subtype Predicts Disease Progression in Women of Sub-Saharan Africa

C. Morrison, Pai-Lien Chen, C. Kwok, 2016, EBioMedicine.

First trial of the HIV-1 vaccine in Africa: Ugandan experience

P. Kaleebu, D. Hom, J. Ellner, 2002, BMJ : British Medical Journal.

Cellular immunity to human immunodeficiency virus type 1 (HIV-1) clades: relevance to HIV-1 vaccine trials in Uganda.

B. Walker, J. Ellner, R. Mugerwa, 2000, The Journal of infectious diseases.

Response to nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-infected children with perinatal exposure to single-dose nevirapine.

F. Ssali, C. Kityo, P. Mugyenyi, 2009, AIDS research and human retroviruses.

Tuberculosis incidence is high in HIV-infected African children but is reduced by co-trimoxazole and time on antiretroviral therapy

A. Crook, A. Walker, P. Musoke, 2016, BMC Medicine.

Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance

P. Weidle, P. Mugyenyi, J. Mermin, 2002, The Lancet.

Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial.

A. Breckenridge, P. Kaleebu, D. Pillay, 2010, Lancet.

HIV drug resistance among adults and children in sub-Saharan Africa

P. Mugyenyi, E. Kaudha, V. Musiime, 2013 .

High Rate of HIV Resuppression After Viral Failure on First-line Antiretroviral Therapy in the Absence of Switch to Second-line Therapy

A. Breckenridge, P. Kaleebu, D. Pillay, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Discontinuation and Modification of Highly Active Antiretroviral Therapy in HIV-Infected Ugandans: Prevalence and Associated Factors

E. Katabira, F. Ssali, P. Mugyenyi, 2007, Journal of acquired immune deficiency syndromes.

Emerging HIV-1 drug resistance after roll-out of antiretroviral therapy in sub-Saharan Africa

Peter Mugyenyi, Raph L Hamers, C. Kityo, 2013, Current opinion in HIV and AIDS.

HIV Drug Resistance Among Children Initiating First-Line Antiretroviral Treatment in Uganda

T. F. Rinke de Wit, T. S. Boender, C. Kityo, 2016, AIDS research and human retroviruses.

Second-line HIV Treatment in Ugandan Children: Favorable Outcomes and No Protease Inhibitor Resistance

T. F. Rinke de Wit, T. S. Boender, C. Kityo, 2016, Journal of tropical pediatrics.

Assessment of second-line antiretroviral regimens for HIV therapy in Africa.

P. Easterbrook, A. Siika, A. Kambugu, 2014, The New England journal of medicine.

The Impact of Different CD4 Cell-Count Monitoring and Switching Strategies on Mortality in HIV-Infected African Adults on Antiretroviral Therapy: An Application of Dynamic Marginal Structural Models

J. Robins, M. Petersen, A. Walker, 2015, American journal of epidemiology.

Identification of gaps for implementation science in the HIV prevention, care and treatment cascade; a qualitative study in 19 districts in Uganda

C. Kityo, F. Bajunirwe, P. Mugyenyi, 2016, BMC Research Notes.

Validation of World Health Organisation HIV/AIDS Clinical Staging in Predicting Initiation of Antiretroviral Therapy and Clinical Predictors of Low CD4 Cell Count in Uganda

E. Katabira, K. Ekoru, J. Hahn, 2011, PloS one.

Decreased serum opsonic activity against Streptococcus pneumoniae in human immunodeficiency virus-infected Ugandan adults.

K. Moji, R. Mugerwa, P. Mugyenyi, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

A Single CD4 Test with 250 Cells/Mm3 Threshold Predicts Viral Suppression in HIV-Infected Adults Failing First-Line Therapy by Clinical Criteria

C. Gilks, E. Katabira, A. Walker, 2013, PloS one.

Factors Associated with Intention to Conceive and its Communication to Providers Among HIV Clients in Uganda

G. Wagner, S. Linnemayr, C. Kityo, 2012, Maternal and Child Health Journal.

A qualitative exploration of the impact of HIV and ART on social disruption and household continuity in Uganda

Alexis K. Huynh, G. Ryan, G. Wagner, 2011, African journal of AIDS research : AJAR.

Sensitive detection of HIV-1 resistance to Zidovudine and impact on treatment outcomes in low- to middle-income countries

E. Arts, A. Poon, Michael Crawford, 2017, Infectious Diseases of Poverty.

Late Presentation With HIV in Africa: Phenotypes, Risk, and Risk Stratification in the REALITY Trial

J. Seeley, K. Maitland, A. Shali, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

HIV Drug Resistance Mutations in Non-B Subtypes After Prolonged Virological Failure on NNRTI-Based First-Line Regimens in Sub-Saharan Africa

P. Easterbrook, K. Wools-Kaloustian, C. Kityo, 2017, Journal of acquired immune deficiency syndromes.

Therapeutic immunization in HIV infected Ugandans receiving stable antiretroviral treatment: a Phase I safety study.

F. Ssali, C. Kityo, P. Mugyenyi, 2011, Vaccine.

Treatment failure and drug resistance is more frequent in HIV-1 subtype D versus subtype A-infected Ugandans over a 10-year study period

E. Arts, C. Kityo, B. Rodriguez, 2013, AIDS.

Third‐line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource‐limited settings: ACTG A5288 strategy trial

R. Schooley, R. Gross, J. Mellors, 2022, Journal of the International AIDS Society.

Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trial

Kenneth A. Freedberg, Rochelle P. Walensky, Milton C. Weinstein, 2012, AIDS.

Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy.

I. Williams, C. Gilks, D. Gibb, 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

HIV-Specific IL-10-Positive CD8+ T Cells Are Increased in Advanced Disease and Are Associated with Decreased HIV-Specific Cytolysis1

F. Ssali, P. Mugyenyi, H. Cao, 2006, The Journal of Immunology.

Lymphoid tissue fibrosis is associated with impaired vaccine responses

M. Lederman, R. Koup, D. Douek, 2018, The Journal of clinical investigation.

Presence of distinct subsets of cytolytic CD8+ T cells in chronic HIV infection.

N. Jones, F. Ssali, P. Mugyenyi, 2006, AIDS research and human retroviruses.

HIV-1 risk and vaccine acceptability in the Ugandan military.

M. Vjecha, D. Hom, J. Ellner, 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Determinants of Clinician Knowledge on Aging and HIV/AIDS: A Survey of Practitioners and Policy Makers in Kampala District, Uganda

Sujal M. Parikh, C. Kityo, H. Mayanja-Kizza, 2013, PloS one.

Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort

C. Gilks, J. Darbyshire, E. Katabira, 2010, The Lancet.

Resistance to antiretroviral therapy among patients in Uganda.

K. Hertogs, B. Larder, S. Bloor, 2001 .

Antiretroviral treatment in Africa.

E. Karita, H. Taelman, R. Colebunders, 1997, AIDS.

Diversity of the vif gene of human immunodeficiency virus type 1 in Uganda.

J. Kühn, H. Eggers, P. Mugyenyi, 1997, The Journal of general virology.

Impact of HIV Antiretroviral Therapy on Depression and Mental Health Among Clients With HIV in Uganda

G. Wagner, Jeffrey A. Garnett, C. Kityo, 2012, Psychosomatic medicine.

Understanding the influence of depression on self-efficacy, work status and condom use among HIV clients in Uganda.

G. Wagner, I. Holloway, C. Kityo, 2011, Journal of psychosomatic research.

Sexual behaviour among persons living with HIV/AIDS in Kampala, Uganda.

F. Ssali, C. Kityo, P. Mugyenyi, 2010, East African medical journal.

Lessons From Africa

W. El-Sadr, K. D. de Cock, P. Mugyenyi, 2010, Journal of acquired immune deficiency syndromes.

O087 Leveraging existing HIV/AIDS infrastructure for rheumatic heart disease care in Uganda: a collaborative disease surveillance and management program

C. Longenecker, M. Kamya, D. Simon, 2014 .

Evolution of Protease Inhibitor Resistance in Human Immunodeficiency Virus Type 1 Infected Patients Failing Protease Inhibitor Monotherapy as Second-line Therapy in Low-income Countries: An Observational Analysis Within the EARNEST Randomized Trial

P. Easterbrook, N. French, H. Namata, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Nevirapine clearance from plasma in African adults stopping therapy: a pharmacokinetic substudy

A. Walker, S. Khoo, D. Gibb, 2007, AIDS.

Flat-line funding for PEPFAR: a recipe for chaos

Peter Mugyenyi, P. Mugyenyi, 2009, The Lancet.

Detection of recent HIV infections in African individuals infected by HIV-1 non-B subtypes using HIV antibody avidity.

L. Tavoschi, C. Galli, S. Buttò, 2008, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

A qualitative analysis of the economic impact of HIV and antiretroviral therapy on individuals and households in Uganda.

Alexis K. Huynh, G. Ryan, G. Wagner, 2009, AIDS patient care and STDs.

Role of antiretroviral therapy in improving food security among patients initiating HIV treatment and care

G. Wagner, P. Mugyenyi, B. Ghosh-Dastidar, 2012, AIDS.

Depression in the Pathway of HIV Antiretroviral Effects on Sexual Risk Behavior Among Patients in Uganda

G. Wagner, I. Holloway, C. Kityo, 2012, AIDS and Behavior.

Relative reactivity of the V3 loop PND of HIV-1 subtypes A, B, C, D, and F with sera from selected Ugandan localities

J. Riley, P. Mugyenyi, W. Boto, 2005, Archives of Virology.

Cost Effectiveness Analysis of Clinically Driven versus Routine Laboratory Monitoring of Antiretroviral Therapy in Uganda and Zimbabwe

C. Gilks, J. Darbyshire, J. Kigozi, 2012, PloS one.

A Randomized, Controlled, Trial of Short Cycle Intermittent Compared to Continuous Antiretroviral Therapy for the Treatment of HIV Infection in Uganda

M. Dybul, R. Dewar, C. Hallahan, 2010, PloS one.

HIV-1 drug resistance in antiretroviral-naive patients in sub-Saharan Africa.

C. Kityo, R. Hamers, P. Mugyenyi, 2012, The Lancet. Infectious diseases.

Hiv Reports

A. Walker, C. Musarurwa, D. Gibb, 2022 .

Diverse HIV-1 Drug Resistance Profiles at Screening for ACTG A5288: A Study of People Experiencing Virologic Failure on Second-line ART in Resource Limited Settings.

M. Hughes, R. Gross, J. Mellors, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Diverse Human Immunodeficiency Virus–1 Drug Resistance Profiles at Screening for ACTG A5288: A Study of People Experiencing Virologic Failure on Second-line Antiretroviral Therapy in Resource-limited Settings

R. Gross, J. Ritz, B. Grinsztejn, 2020 .

Absence of HIV-1 Drug Resistance Mutations Supports the Use of Dolutegravir in Uganda.

E. Arts, A. Poon, Richard Gibson, 2018, AIDS research and human retroviruses.

Strengthening Institutional Research Administration in Uganda: A Case Study on Developing Collaborations among Academic and Research Institutions

D. Kaye, P. Mugyenyi, Nelson Kakande, 2012 .

Need for review of prevention of mother-to-child transmission practice especially in discordant couples: a case of mother-to-child transmission of HIV during breast feeding by a mother who tested HIV negative antenatally.

F. Ssali, C. Kityo, P. Mugyenyi, 2007, AIDS.

Empiric Tuberculosis Therapy versus Isoniazid in Advanced HIV-infected Adult Outpatients Initiating Antiretroviral Therapy : a Multi-Country Randomized Controlled Trial

V. Veloso, M. Hosseinipour, J. Kumwenda, 2016 .

Psychosocial Characterization of HIV Clients With Potential To Be Change Agents For HIV Prevention in Uganda

G. Wagner, N. Tumwesigye, P. Mugyenyi, 2012 .

Impact of routine laboratory monitoring over 5 years after antiretroviral therapy (ART)initiation on clinical disease progression of HIV-infected African adults: the DART Trial finalresults

C. Gilks, J. Darbyshire, E. Katabira, 2009 .

Phenotypic and genotypic analyses to guide selection of reverse transcriptase inhibitors in second-line HIV therapy following extended virological failure in Uganda

D. Pillay, J. Kigozi, E. Katabira, 2014, The Journal of antimicrobial chemotherapy.

Cost Effectiveness Analysis of Routine Laboratory or Clinically Driven Strategies for Monitoring Anti-Retroviral Therapy in Uganda and Zimbabwe (DART Trial)

C. Gilks, J. Darbyshire, J. Kigozi, 2009 .

Long-term virological outcomes, failure and acquired resistance in a large cohort of Ugandan children.

T. F. Rinke de Wit, C. Kityo, P. Mugyenyi, 2019, The Journal of antimicrobial chemotherapy.

48 week virological response to a triple nucleoside/nucleotide analogue regimen in adults with HIV infection in Africa within the DART trial.

P. Kaleebu, P. Mugyenyi, D. Yirrell, 2005 .

Lymphoid tissue fibrosis is associated with impaired vaccine responses

M. Lederman, R. Koup, D. Douek, 2018, The Journal of clinical investigation.

Understanding the influence of depression on self-efficacy, work status and condom use among HIV clients in Uganda.

G. Wagner, I. Holloway, C. Kityo, 2011, Journal of psychosomatic research.

Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trial

M. Hughes, R. Schooley, M. Weinstein, 2012, AIDS.

Role of antiretroviral therapy in improving food security among patients initiating HIV treatment and care

G. Wagner, P. Mugyenyi, B. Ghosh-Dastidar, 2012, AIDS.

Global threat from drug resistant HIV in sub-Saharan Africa

T. R. D. Wit, C. Kityo, R. Hamers, 2012, BMJ : British Medical Journal.

Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial

A. Zolopa, V. Veloso, M. Hosseinipour, 2016, The Lancet.

C. Gilks, J. Darbyshire, D. Gibb, 2010, HIV medicine.

Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial

A. Breckenridge, P. Kaleebu, D. Pillay, 2010, The Lancet.

Assessment of second-line antiretroviral regimens for HIV therapy in Africa.

P. Easterbrook, A. Siika, A. Kambugu, 2014, The New England journal of medicine.

HIV-associated anemia after 96 weeks on therapy: determinants across age ranges in Uganda and Zimbabwe.

F. Ssali, C. Kityo, D. Jaganath, 2014, AIDS Research and Human Retroviruses.

Resistance to Antiretroviral Therapy Among Patients in Uganda

K. Hertogs, B. Larder, S. Bloor, 2001, Journal of acquired immune deficiency syndromes.

Causes and Timing of Mortality and Morbidity Among Late Presenters Starting Antiretroviral Therapy in the REALITY Trial

J. Seeley, N. Klein, F. Fitzgerald, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Antiretroviral drug resistance profiles and response to second-line therapy among HIV type 1-infected Ugandan children.

F. Ssali, C. Kityo, R. Colebunders, 2013, AIDS research and human retroviruses.